Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
0874.HKFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
9,749
Cost of Revenue
8,121
Gross Profit
1,628
Gross Margin
16.7%
Operating Income
468
Operating Margin
4.8%
Net Income
369
Net Margin
3.8%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
637
EBITDA Margin
6.5%
2023
12/31/2023
Revenue
9,817
Cost of Revenue
7,973
Gross Profit
1,844
Gross Margin
18.8%
Operating Income
666
Operating Margin
6.8%
Net Income
527
Net Margin
5.4%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
843
EBITDA Margin
8.6%
2022
12/31/2022
Revenue
9,202
Cost of Revenue
7,476
Gross Profit
1,726
Gross Margin
18.8%
Operating Income
660
Operating Margin
7.2%
Net Income
516
Net Margin
5.6%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
809
EBITDA Margin
8.8%
2021
12/31/2021
Revenue
8,972
Cost of Revenue
7,251
Gross Profit
1,720
Gross Margin
19.2%
Operating Income
622
Operating Margin
6.9%
Net Income
484
Net Margin
5.4%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
756
EBITDA Margin
8.4%
2020
12/31/2020
Revenue
8,018
Cost of Revenue
6,660
Gross Profit
1,357
Gross Margin
16.9%
Operating Income
477
Operating Margin
6.0%
Net Income
379
Net Margin
4.7%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
608
EBITDA Margin
7.6%